HCM
CYTK icon

Highlander Capital Management’s Cytokinetics CYTK Stock Holding History

Highlander Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-6,000
Closed -$57K – 826
2014
Q1 		$57K Buy
6,000
+4,500
+300% +$40.7K 0.05% 302
2013
Q4 		$9.75K Sell
1,500
-9,500
-86% -$62.4K 0.01% 668
2013
Q3 		$83.3K Buy
+11,000
New +$118K 0.08% 255

Other funds holding CYTK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
IIM
Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return

Highlander Capital Management's CYTK Position: Q2 2014 in Review

Highlander Capital Management sold out of Cytokinetics (CYTK) in Q2 2014, closing a stake of 6,000 shares — an estimated $57K sold.

Highlander Capital Management first reported a position in CYTK in Q3 2013 and held it in 3 quarters. The position peaked at $83.3K in Q3 2013. 89 funds tracked by Wall St. Rank hold CYTK as of Q2 2014.

  • Highlander Capital Management reported no remaining Cytokinetics position as of Q2 2014 after selling out during the quarter.
  • Highlander Capital Management sold 6,000 Cytokinetics shares in Q2 2014, an estimated $57K.
  • Highlander Capital Management first reported a position in Cytokinetics in Q3 2013 and held it in 3 quarters.
  • Highlander Capital Management's Cytokinetics position peaked at $83.3K in Q3 2013.
  • 89 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2014.

Based on Highlander Capital Management's 13F filing for Q2 2014, filed 11 Aug 2014.